Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

RELGAABI

GABAPENTIN

Standard Dose
200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview RELGAABI is listed in Drugs@FDA under application 204989 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient GABAPENTIN Form and strength CAPSULE;ORAL - 200MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2026-02-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview RELGAABI is listed in Drugs@FDA under application 204989 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient GABAPENTIN Form and strength CAPSULE;ORAL - 200MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2026-02-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.